| Ningbo Kilo Biotechnology Co., Ltd. | China | |||
|---|---|---|---|---|
![]() | www.kilobio.com | |||
![]() | +8613989352104 | |||
![]() | terry.zhang@kilobio.com | |||
![]() | QQ Chat | |||
![]() | WeChat: Wenzhou Medical University | |||
| Chemical distributor since 2023 | ||||
| chemBlink Standard supplier since 2023 | ||||
| Classification | Biochemical >> Peptide |
|---|---|
| Name | Survodutide |
| Synonyms | 18-[[(1S)-4-[[2-[[(2S)-1-[[2-[[(2S)-1-[[2-[[2-[[(5S)-5-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[1-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]cyclobutanecarbonyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]propanoyl]amino]hexanoyl]amino]-3-carboxypropanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-carboxy-4-oxobutyl]amino]-18-oxooctadecanoic acid |
| Molecular Structure | ![]() |
| Molecular Formula | C192H289N47O61 |
| Molecular Weight | 4231.63 |
| CAS Registry Number | 2805997-46-8 |
| SMILES | CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCNC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)C7(CCC7)NC(=O)[C@H](CC8=CNC=N8)N |
|
Survodutide illustrates a pharmacological idea that is easy to miss when peptide drugs are described by a single hormone name. It is designed to activate both the glucagon receptor and the glucagon-like peptide-1 receptor. These are distinct receptors, even though both respond to related peptide hormones. A dual agonist is one molecule with activity at both, rather than a mixture of two separate medicines. The distinction matters because the natural signals do different jobs. Glucagon helps maintain circulating glucose, particularly when the body needs to mobilize fuel. GLP-1 participates in meal-related signaling and can influence appetite and insulin secretion. Pairing activities is a design hypothesis: the overall metabolic response may differ from that produced by either signal alone. A receptor assay can verify engagement of a target, but cannot establish the net result across organs or over time. A randomized, double-blind phase 2 study published in 2024 compared survodutide with placebo in adults with overweight or obesity without diabetes. It was a dose-finding trial, intended to characterize the response and tolerability across assigned groups. The investigators observed weight changes that differed from placebo, and gastrointestinal adverse events were common in treated groups. Both findings matter when evaluating a candidate. The change on a scale does not summarize whether participants could tolerate the intervention or remain in a study. Later cardiovascular research illustrates a different choice of endpoint. The sponsor's November 2026 report on SYNCHRONIZE-CVOT described a phase 3 comparison focused on major cardiovascular events in people with obesity and elevated cardiovascular risk. The sponsor reported that the trial met its prespecified cardiovascular safety objective versus placebo. That objective is different from demonstrating that treatment prevents cardiovascular events, and neither is equivalent to a weight measurement. Looking at the question specified by each trial prevents a favorable result in one category from being used as evidence in another. Even within an individual trial, different measurements can reflect different aspects of the intervention. A participant who stops taking the assigned intervention can still contribute information to a randomized comparison. Analyses based on continued treatment answer a different question from comparisons based on original assignment. This distinction is particularly relevant when treatment tolerability affects whether participants remain on their assigned intervention. Interpreting clinical evidence requires attention to the comparison made, not only the result highlighted. The two receptor activities are also distinct from the way a peptide is delivered. A study evaluates a defined preparation and schedule, and receptor identity alone cannot establish equivalence between preparations. Purity, formulation and stability can alter the amount of intact material available for biological action. These differences are especially relevant for peptides, which can be broken down or behave differently outside the conditions under which they were tested. The chemical identity record identifies a substance, but it does not certify a finished formulation. Nor is a registry entry evidence of an approved indication. A publication about a clinical trial and a registration entry for its molecule serve different scientific purposes. The trial answers a bounded question about its participants, comparison, and observation period. It does not establish every long-term outcome, isolate the contribution of each receptor, or justify extrapolating to an untested preparation. The scientific story is the attempt to combine two hormonal signals within one defined peptide, and the need for controlled studies to evaluate what that combination actually does. References: 1. Randomised phase 2 study of survodutide in obesity. Lancet Diabetes Endocrinol (2024). https://pubmed.ncbi.nlm.nih.gov/38330987/ 2. FDA GSRS. Survodutide substance identity. https://precision.fda.gov/uniisearch/srs/unii/2ALA66NS64 3. Boehringer Ingelheim. Sponsor report on SYNCHRONIZE-CVOT (9 November 2026). https://www.boehringer-ingelheim.com/us/human-health/metabolic-diseases/obesity/synchronize-cvot-trial-results-presented-aha |
| Market Analysis Reports |